Insulet Corp at Raymond James Institutional Investors Conference Transcript

Mar 07, 2023 / 02:15PM GMT
Jayson Tyler Bedford - Raymond James & Associates, Inc., Research Division - MD & Senior Medical Supplies and Devices Analyst

All right. Good morning. I think we'll start. Welcome to the 44th Annual Raymond James Institutional Investors Conference. My name is Jayson Bedford. I cover the medical technology sector here. It's really our pleasure to have with us the team from Insulet. Insulet has been a loyal participant in this conference for the last decade. And I think, I was looking back a decade ago, it was sub-$2 billion in market cap. So it's been a wonderful growth story over the years.

With us today, we have the company's CEO, Jim Hollingshead. We have the company's CFO, Wayde McMillan; and VP of IR, Deb Gordon. So with that, I'm going to hand it over to Jim.

James R. Hollingshead - Insulet Corporation - President, CEO & Director

Thanks, Jayson, and good morning, everybody. Thanks for coming today. Let me start by introducing you to Christian, who you see here on this slide. Christian is 9 years old. And if you look really closely, on

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot